Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

Phase 3

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Rituximab
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Vindesine
Drug: Bleomycin
Drug: Prednisone

First Posted Date: 2017-01-12

Last Posted Date: 2017-07-28

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 402

Registration Number: NCT03018626

Locations: 🇨🇳
Ru Feng, Guangzhou, Guangdong, China

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma
Recurrent Indolent Adult Non-Hodgkin Lymphoma
Refractory Indolent Adult Non-Hodgkin Lymphoma
Refractory Follicular Lymphoma
Recurrent Follicular Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Drug: Cytarabine
Drug: Etoposide
Biological: Filgrastim
Drug: Lenalidomide
Drug: Melphalan
Biological: Rituximab

First Posted Date: 2017-01-12

Last Posted Date: 2023-02-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT03019640

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

Phase 2

Active, not recruiting

Conditions: Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Biological: Nivolumab

First Posted Date: 2017-01-11

Last Posted Date: 2024-10-09

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 78

Registration Number: NCT03016871

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Paediatric Hepatic International Tumour Trial

Phase 3

Active, not recruiting

Conditions: Carcinoma, Hepatocellular
Hepatoblastoma

Interventions: Drug: Cisplatin
Drug: Doxorubicin
Drug: Carboplatin
Drug: Gemcitabine
Drug: 5Fluorouracil
Drug: Oxaliplatin
Drug: Vincristine
Drug: Etoposide
Drug: Sorafenib
Drug: Irinotecan

First Posted Date: 2017-01-11

Last Posted Date: 2024-05-13

Lead Sponsor: University of Birmingham

Target Recruit Count: 450

Registration Number: NCT03017326

Locations: 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Woluwe-Saint-Lambert, Belgium
🇮🇪
Children's Health Ireland Crumlin, Dublin, Ireland
🇮🇱
Schneider Children's Medical Center, Petach Tikva, Israel

and more 28 locations

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

First Posted Date: 2017-01-02

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 475

Registration Number: NCT03007147

Locations: 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States

and more 224 locations

2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Thalidomide
Drug: Dexamethasone
Drug: Daratumumab
Drug: Cisplatin
Drug: Adriamycin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Melphalan
Procedure: ASCT
Drug: Lenalidomide
Drug: Bortezomib

First Posted Date: 2016-12-28

Last Posted Date: 2024-10-09

Lead Sponsor: University of Arkansas

Target Recruit Count: 50

Registration Number: NCT03004287

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC

Phase 1

Terminated

Conditions: Stage IIIA Non-Small Cell Lung Cancer

Interventions: Drug: Cisplatin
Drug: Etoposide
Drug: Pembrolizumab
Drug: Radiation

First Posted Date: 2016-12-09

Last Posted Date: 2022-12-19

Lead Sponsor: Nathan Pennell, MD, PhD

Target Recruit Count: 9

Registration Number: NCT02987998

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

Phase 1

Conditions: T Cell Non-Hodgkin's Lymphoma

Interventions: Drug: Chidamide
Drug: Cyclophosphamide
Drug: Epirubicin
Drug: Vindesine
Drug: Etoposide
Drug: Prednisone

First Posted Date: 2016-12-08

Last Posted Date: 2016-12-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 100

Registration Number: NCT02987244

Locations: 🇨🇳
Peking Union medical college hospital, Beijing, Beijing, China
🇨🇳
Tianjin medical universty cancer institute & hospital, Tianjin, Tianjin, China